Drug Trial Radar · NCT04513912
A Study of Seltorexant Compared to Quetiapine XR as Adjunctive Therapy to Antidepressants in Adult and Elderly Participants With Major Depressive Disorder With Insomnia Symptoms Who Have Responded Inadequately to Antidepressant Therapy
Last checked: Nov 20, 2026Latest source record: Nov 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
757
Actual
Start
Sep 15, 2020
Primary completion
Oct 3, 2023
Study completion Oct 3, 2023
Sponsor
- Lead sponsor
- Janssen Research & Development, LLCJohnson & Johnson (Janssen) (JNJ)
- Sponsor type
- Industry
- First posted
- Aug 14, 2020
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 74 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to assess the efficacy of seltorexant compared with quetiapine extended-release (XR) as adjunctive therapy to an antidepressant drug in treatment response in participants with major depressive disorder with insomnia symptoms (MDDIS) who have had an inadequate response to current antidepressant therapy with a selective serotonin reuptake inhibitor (SSRI) or serotonin-norepinephrine reuptake inhibitor (SNRI).
Conditions
- Depressive Disorder, Major
Interventions
SeltorexantDrug
Participants will receive seltorexant over-encapsulated tablet orally.
Matching placebo to SeltorexantDrug
Participants will receive placebo over-encapsulated tablet matching to seltorexant orally.
Quetiapine XRDrug
Participants will receive quetiapine XR capsule orally.
Matching placebo to Quetiapine XRDrug
Participants will receive placebo capsule matching to quetiapine XR orally.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Participants Who Achieved Response (Greater Than or Equal to [>=50] Percent Improvement in Montgomery-Asberg Depression Rating Scale [MADRS] Total Score From Baseline) at Week 26Time frame: Week 26
Locations
175 sites in 15 countries. Site status is shown where the registry gives one.
University of Alabama at Birmingham
Birmingham, Alabama
SW Biomedical Research LLC
Tucson, Arizona
Proscience Research Group
Culver City, California
Pharmacology Research Institute
Encino, California
Collaborative NeuroScience Network
Garden Grove, California
Collaborative NeuroScience Network
Long Beach, California
Pharmacology Research Institute
Los Alamitos, California
CalNeuro Research
Los Angeles, California
Pharmacology Research Institute
Newport Beach, California
NRC Research Institute
Orange, California
Pacific Neuropsychiatric Specialists
Orange, California
CNRI-Los Angeles, LLC
Pico Rivera, California
Prospective Research Innovations Inc
Rancho Cucamonga, California
Anderson Clinical Research
Redlands, California
University of California at San Diego
San Diego, California
National Research Institute
Santa Ana, California
CI Trials
Santa Ana, California
CMB Clinical Trials
Santee, California
Schuster Medical Research Institute
Sherman Oaks, California
Pacific Clinical Research Medical Group
Upland, California
Hartford Hospital
Hartford, Connecticut
Moonshine Research Center, Inc
Doral, Florida
Velocity Clinical Research, Hallandale Beach
Hallandale, Florida
Indago Research & Health Center Inc
Hialeah, Florida
New Life Medical Research Center, Inc.
Hialeah, Florida
Amedica Research Institute Inc
Hialeah, Florida
Meridien Research
Lakeland, Florida
Premier Clinical Research
Miami, Florida
Global Medical Institutes
Miami, Florida
Miami Jewish Health System
Miami, Florida
Clinical Neuroscience Solutions
Orlando, Florida
Synexus Research Orlando
Orlando, Florida
University of South Florida
Tampa, Florida
Compass Research LLC-Bioclinica Research
The Villages, Florida
Synexus Clinical Research US Inc
Atlanta, Georgia
Atlanta Center for Medical Research
Atlanta, Georgia
iResearch Atlanta LLC
Decatur, Georgia
Psych Atlanta, P.C.
Marietta, Georgia
Chicago Research Center
Chicago, Illinois
Capstone Clinical Research
Libertyville, Illinois
Showing 40 of 175 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.